Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | MGLL | Q99685 | 11/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 4/20 | 0.50 |
| ▸ | CCR3 | P51677 | 4/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14834114 | 0.93 | SLC6A2 (0.57) | EPHX2MGLLSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21824824 | 0.92 | MGLL (0.55) | EPHX2MGLLSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2636481 | 0.86 | EPHX2 (0.56) | EPHX2MGLLSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14834074 | 0.86 | SLC6A2 (0.55) | EPHX2MGLLSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14834077 | 0.86 | SLC6A2 (0.55) | EPHX2MGLLSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14834233 | 0.86 | SLC6A2 (0.55) | EPHX2MGLLSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4555874 | 0.85 | GPR119 (0.60) | EPHX2MGLLGPR119 | |
| SCHEMBL2636485 | 0.85 | EPHX2 (0.57) | EPHX2MGLLSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2454389 | 0.84 | GPR119 (0.49) | EPHX2MGLLHRH1CCR3CNR1 | |
| SCHEMBL3290157 | 0.83 | HRH3 (0.64) | EPHX2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723331-B2 | Thienopyrimidine compounds and uses thereof | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| EP-1996545-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | Boehringer Ingelheim International GmbH (DE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080051405-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| WO-2007106705-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051405-A1 | Therapeutic Agents | GPR119, HTT, IAPP | EPHX2 1731/4885MGLL 509/4885SLC6A2 1701/4885 |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885MGLL 107/4885SLC6A2 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.